10 September 2024: Patients taking sulthiame (brand name Ospolot), a drug currently in use for epilepsy, experienced a reduction in their symptoms of obstructive sleep apnoea (OSA) according to results of a clinical trial presented at the European Respiratory Society (ERS) Congress in Vienna Austria [1]. Patients with OSA often snore loudly, their breathing starts…
Enhancing MRI with AI to improve diagnosis of brain disorders
Study introduces a machine-learning model to synthesise high-quality MRIs from lower-quality images There is growing interest in using machine learning to enhance imaging data captured by magnetic resonance imaging (MRI) technology. Recent studies show that ultra-high-field MRI at 7 Tesla (7T) could have far greater resolution and clinical advantages over high-field MRI at 3T in…
Parkinson’s disease therapy Vyalev gets FDA approval
AbbVie announced on 17th October that the US Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The treatment is approved in 35 countries. The approval was supported by…
Human-specific genes linked to brain development and disorders
Link discovered between two human-specific genes and the SYNGAP1 gene, which is associated with intellectual disability and autism spectrum disorders 14th October 2024: A team of researchers led by Prof. Pierre Vanderhaeghen (VIB-KU Leuven), in collaboration with scientists from Columbia University and Ecole Normale Supérieure, has discovered a link between two human-specific genes, SRGAP2B and…
Near infrared light treatment in traumatic brain injury
Monday 14th October, 2024: Birmingham scientists have shown light therapy delivered transcranially can aid tissue repair after mild traumatic brain injury (mTBI). Their research, published in Bioengineering & Translational Medicine, indicates that this novel method could result in a new treatment option in an area of medicine that currently has few, if any, treatment options. …
Ophthalmic acid – its role in motor function control
Brain molecule reverses movement deficits of Parkinson’s, offering new therapeutic target October 4th 2024: A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target…
Is there demand for digital health education in medical education programmes?
Give your feedback via online survey Ain Shams University Virtual Hospital (AVH) on behalf of the Global South Health Alliance (GSHA) is inviting specialists to contribute to research on The Demand for Integrating Digital Health Curricula into Medical Education Programmes. Technologies like electronic medical records, telemedicine and artificial intelligence are increasingly being used in all…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
Role of hippocampus in skilled movement control
Researchers at the University of Birmingham have uncovered a surprising role 26 September 2024: Researchers at the University of Birmingham have uncovered a surprising role of the hippocampus – linking this part of the brain to the control of skilled actions such as handwriting, typing, and playing music. The hippocampus is traditionally associated with memory…
